Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals ROA 2010-2025 | IRWD

Current and historical return on assets (ROA) values for Ironwood Pharmaceuticals (IRWD) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
  
Ironwood Pharmaceuticals ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2025-03-31 $-0.03B $0.33B -8.74%
2024-12-31 $0.00B $0.35B 0.25%
2024-09-30 $0.00B $0.39B -0.47%
2024-06-30 $0.01B $0.40B 1.97%
2024-03-31 $-1.05B $0.44B -206.58%
2023-12-31 $-1.00B $0.47B -145.59%
2023-09-30 $-0.95B $0.52B -112.56%
2023-06-30 $-0.92B $0.60B -94.08%
2023-03-31 $0.18B $1.16B 17.04%
2022-12-31 $0.18B $1.10B 16.67%
2022-09-30 $0.17B $1.04B 15.81%
2022-06-30 $0.17B $0.98B 16.23%
2022-03-31 $0.53B $1.08B 49.07%
2021-12-31 $0.53B $1.13B 55.40%
2021-09-30 $0.53B $1.08B 65.35%
2021-06-30 $0.51B $1.01B 76.48%
2021-03-31 $0.14B $0.60B 27.13%
2020-12-31 $0.11B $0.56B 22.12%
2020-09-30 $0.07B $0.49B 16.52%
2020-06-30 $0.06B $0.44B 14.89%
2020-03-31 $0.05B $0.40B 12.63%
2019-12-31 $0.02B $0.40B 5.93%
2019-09-30 $0.00B $0.33B -1.19%
2019-06-30 $-0.20B $0.32B -55.70%
2019-03-31 $-0.26B $0.36B -60.08%
2018-12-31 $-0.28B $0.33B -58.00%
2018-09-30 $-0.25B $0.42B -45.93%
2018-06-30 $-0.11B $0.62B -18.51%
2018-03-31 $-0.11B $0.57B -17.07%
2017-12-31 $-0.12B $0.61B -17.75%
2017-09-30 $-0.14B $0.63B -20.87%
2017-06-30 $-0.14B $0.71B -20.22%
2017-03-31 $-0.12B $0.70B -17.16%
2016-12-31 $-0.08B $0.71B -11.95%
2016-09-30 $-0.08B $0.73B -12.36%
2016-06-30 $-0.10B $0.70B -15.15%
2016-03-31 $-0.12B $0.60B -19.61%
2015-12-31 $-0.14B $0.62B -25.91%
2015-09-30 $-0.17B $0.61B -34.91%
2015-06-30 $-0.16B $0.65B -39.39%
2015-03-31 $-0.17B $0.31B -51.18%
2014-12-31 $-0.19B $0.33B -51.88%
2014-09-30 $-0.20B $0.35B -57.67%
2014-06-30 $-0.22B $0.37B -64.23%
2014-03-31 $-0.23B $0.42B -65.06%
2013-12-31 $-0.27B $0.28B -83.11%
2013-09-30 $-0.27B $0.33B -83.79%
2013-06-30 $-0.16B $0.38B -52.28%
2013-03-31 $-0.13B $0.33B -51.83%
2012-12-31 $-0.07B $0.23B -31.23%
2012-09-30 $-0.04B $0.25B -15.75%
2012-06-30 $-0.11B $0.21B -47.40%
2012-03-31 $-0.08B $0.25B -35.81%
2011-12-31 $-0.07B $0.21B -27.37%
2011-09-30 $-0.07B $0.22B -26.87%
2011-06-30 $-0.06B $0.25B -20.21%
2011-03-31 $-0.06B $0.27B -18.33%
2010-12-31 $-0.05B $0.30B -16.75%
2010-09-30 $-0.07B $0.31B -23.07%
2010-06-30 $-0.07B $0.32B -27.98%
2010-03-31 $-0.07B $0.34B -42.46%
2009-12-31 $-0.07B $0.16B -91.03%
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.092B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $86.587B 32.48
Zoetis (ZTS) United States $72.382B 27.01
Daiichi Sankyo, - (DSNKY) Japan $50.265B 25.57
Takeda Pharmaceutical (TAK) Japan $46.360B 9.22
Sandoz Group AG (SDZNY) Switzerland $21.683B 0.00
Summit Therapeutics (SMMT) United States $19.198B 0.00
Merck (MKKGY) Germany $16.795B 12.31
United Therapeutics (UTHR) United States $13.877B 12.28
Shionogi (SGIOY) Japan $13.799B 13.82
Neurocrine Biosciences (NBIX) United States $11.894B 40.74
IPSEN (IPSEY) France $9.790B 0.00
Orion OYJ (ORINY) Finland $9.323B 25.21
Corcept Therapeutics (CORT) United States $8.345B 67.84
Stevanato Group S.p.A (STVN) Italy $6.756B 41.31
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $5.941B 0.00
Grifols, S.A (GRFS) Spain $5.576B 0.00
Ionis Pharmaceuticals (IONS) United States $5.249B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.875B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.987B 10.47
Crinetics Pharmaceuticals (CRNX) United States $2.786B 0.00
Hypermarcas (HYPMY) Brazil $2.616B 17.21
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.244B 12.14
BioCryst Pharmaceuticals (BCRX) United States $2.216B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.934B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.719B 0.00
Evotec AG (EVO) Germany $1.680B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.659B 0.00
Indivior (INDV) United States $1.553B 6.58
ARS Pharmaceuticals (SPRY) United States $1.471B 0.00
Guardian Pharmacy Services (GRDN) United States $1.389B 0.00
Dyne Therapeutics (DYN) United States $1.329B 0.00
Ocular Therapeutix (OCUL) United States $1.163B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.092B 21.84
Harrow (HROW) United States $0.950B 0.00
Ardelyx (ARDX) United States $0.950B 0.00
Collegium Pharmaceutical (COLL) United States $0.927B 5.00
Avadel Pharmaceuticals (AVDL) Ireland $0.883B 0.00
Enliven Therapeutics (ELVN) United States $0.805B 0.00
Cronos Group (CRON) Canada $0.782B 0.00
Xeris Biopharma Holdings (XERS) United States $0.755B 0.00
Akebia Therapeutics (AKBA) United States $0.751B 0.00
AleAnna (ANNA) United States $0.675B 0.00
KalVista Pharmaceuticals (KALV) United States $0.570B 0.00
Elite Pharmaceuticals (ELTP) United States $0.566B 0.00
USANA Health Sciences (USNA) United States $0.548B 11.91
Regulus Therapeutics (RGLS) United States $0.546B 0.00
Xencor (XNCR) United States $0.539B 0.00
Bioventus (BVS) United States $0.536B 13.60
Relay Therapeutics (RLAY) United States $0.499B 0.00
Savara (SVRA) United States $0.491B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.473B 0.00
Zevra Therapeutics (ZVRA) United States $0.473B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.465B 0.00
Altimmune (ALT) United States $0.463B 0.00
CytoDyn (CYDY) United States $0.424B 0.00
Siga Technologies (SIGA) United States $0.422B 8.82
Oruka Therapeutics (ORKA) United States $0.410B 0.00
Tourmaline Bio (TRML) United States $0.393B 0.00
Verve Therapeutics (VERV) United States $0.389B 0.00
Organogenesis (ORGO) United States $0.368B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.339B 9.15
Heron Therapeutics (HRTX) United States $0.282B 0.00
Nature's Sunshine Products (NATR) United States $0.262B 24.19
Aquestive Therapeutics (AQST) United States $0.233B 0.00
MediWound (MDWD) Israel $0.220B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.212B 0.00
ProKidney (PROK) United States $0.208B 0.00
Nanobiotix S.A (NBTX) France $0.172B 0.00
Wellgistics Health (WGRX) United States $0.170B 0.00
OmniAb (OABI) United States $0.169B 0.00
Avita Medical (RCEL) United States $0.166B 0.00
Journey Medical (DERM) United States $0.163B 0.00
4D Molecular Therapeutics (FDMT) United States $0.162B 0.00
Esperion Therapeutics (ESPR) United States $0.157B 0.00
Profound Medical (PROF) Canada $0.154B 0.00
Liminatus Pharma (LIMN) $0.145B 0.00
Aclaris Therapeutics (ACRS) United States $0.136B 0.00
Aldeyra Therapeutics (ALDX) United States $0.133B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Korro Bio (KRRO) United States $0.130B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.124B 0.00
Lyell Immunopharma (LYEL) United States $0.123B 0.00
Nektar Therapeutics (NKTR) United States $0.122B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Protara Therapeutics (TARA) United States $0.121B 0.00
Larimar Therapeutics (LRMR) United States $0.120B 0.00
VAXART, INC (VXRT) United States $0.106B 0.00
Achieve Life Sciences (ACHV) Canada $0.105B 0.00
Cassava Sciences (SAVA) United States $0.102B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Lexeo Therapeutics (LXEO) United States $0.094B 0.00
Cardiol Therapeutics (CRDL) Canada $0.091B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.091B 0.00
Fractyl Health (GUTS) United States $0.088B 0.00
Arch Biopartners (ACHFF) Canada $0.084B 0.00
Galectin Therapeutics (GALT) United States $0.081B 0.00
Champions Oncology (CSBR) United States $0.080B 13.18
Pyxis Oncology (PYXS) United States $0.076B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.076B 56.44
ESSA Pharma (EPIX) Canada $0.075B 0.00
Inotiv (NOTV) United States $0.073B 0.00
Surrozen (SRZN) United States $0.068B 0.00
Dominari Holdings (DOMH) United States $0.067B 0.00
Assertio Holdings (ASRT) United States $0.067B 0.00
Vivani Medical (VANI) United States $0.067B 0.00
Unicycive Therapeutics (UNCY) United States $0.067B 0.00
Telomir Pharmaceuticals (TELO) United States $0.063B 0.00
Context Therapeutics (CNTX) United States $0.062B 0.00
Nutriband (NTRB) United States $0.061B 0.00
Metagenomi (MGX) United States $0.061B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.057B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Prelude Therapeutics (PRLD) United States $0.050B 0.00
Century Therapeutics (IPSC) United States $0.048B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.048B 0.00
Mural Oncology (MURA) Ireland $0.047B 0.00
PMV Pharmaceuticals (PMVP) United States $0.047B 0.00
NRx Pharmaceuticals (NRXP) United States $0.045B 0.00
Avalo Therapeutics (AVTX) United States $0.041B 0.00
Karyopharm Therapeutics (KPTI) United States $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Acrivon Therapeutics (ACRV) United States $0.037B 0.00
Rafael Holdings (RFL) United States $0.035B 0.00
FibroGen (FGEN) United States $0.033B 0.00
SCYNEXIS (SCYX) United States $0.030B 0.00
PolyPid (PYPD) Israel $0.028B 0.00
China SXT Pharmaceuticals (SXTC) China $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.023B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Tempest Therapeutics (TPST) United States $0.023B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
Jupiter Neurosciences (JUNS) United States $0.021B 0.00
Lipocine (LPCN) United States $0.019B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.018B 0.00
DURECT (DRRX) United States $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
VYNE Therapeutics (VYNE) United States $0.016B 0.00
GlycoMimetics (GLYC) United States $0.016B 0.00
SHINECO (SISI) China $0.015B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.013B 0.00
ProPhase Labs (PRPH) United States $0.013B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
Scienture Holdings (SCNX) United States $0.011B 0.00
Talphera (TLPH) United States $0.010B 0.00
Minerva Neurosciences (NERV) United States $0.010B 1.78
Ainos (AIMD) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Traws Pharma (TRAW) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
Aditxt (ADTX) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00